Autologous Cellular Therapies: Defining the Scope and Obligations of Clinical Innovation A Research Symposium


This multi-disciplinary symposium is aimed at critically reflecting on the ethical, regulatory and conceptual issues surrounding the provision of autologous stem cells and cell-based products as ‘innovative therapies’. Interventions with autologous stem cells are being marketed directly to patients, typically over the Internet across geographical boundaries, for a wide range of serious illnesses and conditions. The global proliferation of these practices has raised concerns about the lack of scientific and clinical justification for these interventions and the possible harms they pose to patient populations vulnerable to exploitation. They have generally emerged from private clinics exploiting weaknesses in regulatory systems across different geographical jurisdictions and misinterpreting porous distinctions between clinical practice, research and innovation. They may also be indicative of a wider global trend to facilitate innovation by reducing legal and regulatory constraints over the use of novel medicines in the marketplace, rather than enabling more effective regulation, and demand critical attention to more clearly define the scope and obligations associated with responsible innovation.

For details on the program please see http://iccec2017.com/research-symposium-autologous-cellular-therapies-defining-scope-and-obligations-clinical-innovation

The symposium will focus on six original research papers with oral commentaries from scholars with internationally-recognized expertise in the empirical, normative, sociological and legal analysis of biomedical innovation, health technologies, and stem cell science.

The program will include an overview on the state of the science from:

  • John Rasko, Centenary Institute, University of Sydney

The symposium will feature research papers from:

  • Leigh Turner, Centre for Bioethics, University of Minnesota
  • Tereza Hendl; Centre for Values, Ethics and the Law in Medicine, University of Sydney
  • Tamra Lysaght & Tsung-Ling Lee; Centre for Biomedical Ethics, NUS
  • Douglas Sipp; Centre for Developmental Biology, RIKEN Institute
  • Christine Hauskeller; Department of Sociology, Philosophy & Anthropology, University of Exeter
  • Cameron Stewart; Sydney Law School, University of Sydney
  • Wendy Lipworth; Centre for Values, Ethics and the Law in Medicine, University of Sydney

With commentaries from:

  • Alastair Campbell; Centre for Biomedical Ethics, NUS
  • Dominique Martin; Faculty of Health, Deakin University
  • Bernadette Richards; Law School, University of Adelaide
  • Sarah Chan: Usher Institute of Population Health Sciences and Informatics, University of Edinburgh
  • Catherine Waldby; ANU College of Arts and Social Sciences
  • Jeremy Sugarman, Berman Institute of Bioethics

This event is supported with funding from the NUS Humanities and Social Sciences Research Fund and is sponsored by the Stem Cell Society, Singapore (SCSS).

  • The event description was updated. Diff#236443 2017-03-31 05:29:23
More updates
Wed May 24, 2017
8:30 AM - 5:30 PM SGT
Add to Calendar
Creation @ MATRIX Level 4. Biopolis
general FULL
Venue Address
Creation @ MATRIX Level 4. Biopolis Singapore
Centre for Biomedical Ethics, National University of Singapore